Hepatitis B Virus News and Research

RSS

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

Occult hepatitis B mutations drive liver cancer growth via Akt mTOR pathway

Occult hepatitis B virus (OBI) infection presents a significant global health challenge, notoriously flying under the radar of standard viral screening while relentlessly driving the pathogenesis of hepatocellular carcinoma (HCC).

22 Jul 2026

Study reveals mechanism underlying HBV-induced liver inflammation

Chronic hepatitis B virus (HBV) infection remains a major cause of global liver morbidity, leading to progressive necroinflammation that often culminates in cirrhosis and hepatocellular carcinoma.

17 Jul 2026

Strategic healthcare interventions bring Japan close to eliminating hepatitis

Hepatitis B (HBV) and hepatitis C (HCV) are viral infections that can lead to health conditions such as cirrhosis, cancer, and potentially death if unmanaged. HBV can be transmitted through sexual contact, blood exposure, and mother-to-child transmission, while HCV is primarily transmitted through blood-to-blood contact.

25 Jun 2026

Optimized extended PCLS culture system extends tissue viability up to two weeks

Precision-cut liver slice (PCLS) technology has long been regarded as a promising ex vivo platform because it preserves the native multicellular architecture of liver tissue.

22 May 2026

Immune cell discovery reveals new pathway for hepatitis B treatment

Fifteen years ago, doctors in Europe noticed a remarkable thing happening in people with chronic hepatitis B infections. When patients went off their medications, the virus started to come back - and then some of the patients were cured.

13 May 2026

Modeling the synergy of maternal screening and newborn HBV vaccination

Hepatitis B virus (HBV) infection acquired at birth or during early infancy can lead to lifelong health complications, including chronic liver disease. Despite longstanding recommendations for prenatal screening, an estimated 12% to 16% of pregnant individuals in the US are not screened for hepatitis B. This gap leaves a portion of newborns at risk for undetected exposure.

28 Apr 2026

Delaying hepatitis B birth vaccines increases infant infection risks

Delaying hepatitis B vaccination after birth increases infections among newborns and decreases their survival rates and quality of life, according to a new Cornell University study.

27 Apr 2026

Long-term study supports tenofovir alafenamide for chronic hepatitis B

Tenofovir alafenamide (TAF) has demonstrated comparable efficacy to tenofovir disoproxil fumarate (TDF), with improved renal and bone safety, in Chinese participants with chronic hepatitis B enrolled in two Phase 3 trials.

24 Apr 2026

AGA update calls for better surveillance of hepatocellular carcinoma

A new update from the American Gastroenterological Association (AGA) urges stronger prevention efforts and better early-detection tools for hepatocellular carcinoma (HCC), the leading cause of cancer-related death in patients with cirrhosis, and the third most common cause of cancer-related death worldwide.

17 Apr 2026

Denmark achieves historic elimination of mother-to-child HIV and syphilis transmission

The World Health Organization (WHO) has certified Denmark for the elimination of mother-to-child transmission (EMTCT) of HIV and syphilis, recognizing the country's sustained commitment to ensuring every child is born free of these infections.

27 Feb 2026

Dynamic viral markers predict treatment response in hepatitis B

The rate of functional cure (HBsAg loss) remains unsatisfactory following pegylated interferon (PEG-IFN) treatment in chronic hepatitis B. To optimize PEG-IFN administration, this study aimed to evaluate virological markers to predict functional cure and/or hepatitis B e antigen (HBeAg) loss.

30 Jan 2026

Diagnostic prognostic and therapeutic relevance of PIVKA-II in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with high hepatitis B virus prevalence.

24 Jan 2026

The CDC just sidelined these childhood vaccines. Here’s what they prevent.

The federal government has drastically scaled back the number of recommended childhood immunizations, sidelining six routine vaccines that have safeguarded millions from serious diseases, long-term disability, and death.

6 Jan 2026

Virus shells use asymmetry to control RNA release and infection

Viruses are typically described as tiny, perfectly geometric shells that pack genetic material with mathematical precision, but new research led by scientists at Penn State reveals a deliberate imbalance in their shape that helps them infect their hosts.

12 Dec 2025

RFK Jr. wants to delay the hepatitis B vaccine. Here’s what parents need to know.

Working out of a tribal-owned hospital in Anchorage, Alaska, liver specialist Brian McMahon has spent decades treating the long shadow of hepatitis B. Before a vaccine became available in the 1980s, he saw the virus claim young lives in western Alaskan communities with stunning speed.

2 Dec 2025

Understanding thrombocytopenia in patients with portal hypertension and chronic liver disease

Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal hypertension (PH) being a primary driver of disease progression and decompensation.

12 Nov 2025

Common viruses sharply raise heart attack and stroke risk, major global review shows

In the largest synthesis to date, researchers reviewed 155 studies linking viral infections, including influenza, SARS-CoV-2, HIV, hepatitis C, and shingles, to increased risks of coronary heart disease, stroke, and heart failure. The findings highlight viral infection prevention and vaccination as underappreciated strategies for cardiovascular protection.

30 Oct 2025

Researchers to study the economics of substance use disorder treatments with $4 million NIDA grant

A team led by Weill Cornell Medicine and University of Miami's Miller School of Medicine investigators has been awarded a five-year, $4 million grant from the National Institute on Drug Abuse (NIDA) for health economics research.